Hualan Biological Vaccine Inc. (SHE:301207)

Hualan Biological Vaccine Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	1,116	1,126	2,409	1,824	1,830	2,425
Other Revenue	1.83	1.83	1.2	1.57	-	1.28
Revenue	1,118	1,128	2,410	1,826	1,830	2,426
Revenue Growth (YoY)	-51.40%	-53.21%	32.03%	-0.23%	-24.59%	131.30%
Cost of Revenue	286.78	286.78	382.02	369.19	354.01	288.64
Gross Profit	831.09	841.03	2,028	1,456	1,476	2,138
Selling, General & Admin	572.03	582.54	1,019	776.35	647.5	915.27
Research & Development	165.73	162.64	91.11	134.64	144.13	110.94
Other Operating Expenses	11.45	10.61	15.18	12.59	10.84	13.25
Operating Expenses	741.1	746.39	1,146	952.36	803.51	1,083
Operating Income	90	94.64	881.98	504.09	672.29	1,055
Interest Expense	-6.08	-6.1	-6.08	-10.69	-13.32	-2
Interest & Investment Income	89.8	89.29	81.93	72.01	28.82	9.4
Currency Exchange Gain (Loss)	0.06	0.06	-0.23	-0.11	0.25	0.23
Other Non Operating Income (Expenses)	0.01	-0.08	-0.15	0.08	-0.19	-0.23
EBT Excluding Unusual Items	173.79	177.81	957.44	565.37	687.85	1,062
Gain (Loss) on Sale of Investments	20.29	24.3	39.68	16.85	14.25	1.86
Gain (Loss) on Sale of Assets	-0	-0.14	-0.2	0.63	-	-
Asset Writedown	0.8	-0.24	-0.25	-0.05	-1	-0.33
Other Unusual Items	11.69	12.82	10.21	6.68	4.65	10.36
Pretax Income	206.58	214.55	1,007	589.48	705.75	1,074
Income Tax Expense	6.87	9.03	146.91	69.84	84.78	149.14
Net Income	199.7	205.52	859.97	519.63	620.97	924.91
Net Income to Common	199.7	205.52	859.97	519.63	620.97	924.91
Net Income Growth	-75.18%	-76.10%	65.50%	-16.32%	-32.86%	146.45%
Shares Outstanding (Basic)	597	598	601	590	540	540
Shares Outstanding (Diluted)	597	598	602	590	540	540
Shares Change (YoY)	-0.93%	-0.71%	2.03%	9.33%	0.01%	-0.24%
EPS (Basic)	0.33	0.34	1.43	0.88	1.15	1.71
EPS (Diluted)	0.33	0.34	1.43	0.88	1.15	1.71
EPS Growth	-74.95%	-75.93%	62.20%	-23.46%	-32.86%	147.05%
Free Cash Flow	337.98	416.45	825.42	196.01	-66.73	161.43
Free Cash Flow Per Share	0.57	0.70	1.37	0.33	-0.12	0.30
Dividend Per Share	0.200	0.200	0.600	0.200	0.133	-
Dividend Growth	-66.67%	-66.67%	200.00%	50.04%	-	-
Gross Margin	74.35%	74.57%	84.15%	79.78%	80.65%	88.10%
Operating Margin	8.05%	8.39%	36.59%	27.61%	36.74%	43.47%
Profit Margin	17.87%	18.22%	35.68%	28.46%	33.94%	38.12%
Free Cash Flow Margin	30.23%	36.93%	34.24%	10.74%	-3.65%	6.65%
EBITDA	230.38	235	1,022	638.51	740.2	1,096
EBITDA Margin	20.61%	20.84%	42.41%	34.98%	40.45%	45.16%
D&A For EBITDA	140.38	140.37	140.33	134.42	67.91	40.85
EBIT	90	94.64	881.98	504.09	672.29	1,055
EBIT Margin	8.05%	8.39%	36.59%	27.61%	36.74%	43.47%
Effective Tax Rate	3.33%	4.21%	14.59%	11.85%	12.01%	13.89%
Revenue as Reported	1,118	1,128	2,410	1,826	1,830	2,426

Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.